| Primary information |
|---|
| sequence ID | Seq_6579 |
| Peptide sequence | RIHWESASLLR |
| CancerPDF_ID | CancerPDF_ID936, CancerPDF_ID9464, CancerPDF_ID9600, |
| PMID | 19795908,26379225,21533267 |
| Protein Name | Complement C3,Complement C3,Complement C3 |
| UniprotKB Entry Name | CO3_HUMAN,CO3_HUMAN,CO3_HUMAN |
| Fluid | Plasma,Plasma,Serum |
| M/Z | 456.58,1367.77,456.58 |
| Charge | 3,NA,3 |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LC-MS,MALDI-TOF,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,MALDI-TOF/TOF,LC/MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Labelled,Label Free,Label Free |
| FDR | less than 7%,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID936, CancerPDF_ID9464, CancerPDF_ID9600, |
| p-Value | NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.3),MASCOT |
| Length | 11,11,11 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,UniprotKB,Swissprot Database (57.4) |
| Modification | NA,NA,NA |
| Number of Patients | "42 normal, 28 patients","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group.,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,NA,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | 533899
|